GB9930768D0 - Composition - Google Patents

Composition

Info

Publication number
GB9930768D0
GB9930768D0 GBGB9930768.8A GB9930768A GB9930768D0 GB 9930768 D0 GB9930768 D0 GB 9930768D0 GB 9930768 A GB9930768 A GB 9930768A GB 9930768 D0 GB9930768 D0 GB 9930768D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical
wound
composition
damaged tissue
inhibitor agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9930768.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB9930768.8A priority Critical patent/GB9930768D0/en
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of GB9930768D0 publication Critical patent/GB9930768D0/en
Priority to PCT/IB2000/001935 priority patent/WO2001049309A2/en
Priority to CA002395487A priority patent/CA2395487A1/en
Priority to JP2001549676A priority patent/JP2003519193A/en
Priority to CO00097188A priority patent/CO5271671A1/en
Priority to EP00981550A priority patent/EP1242120A2/en
Priority to AU18782/01A priority patent/AU1878201A/en
Priority to GT200000224A priority patent/GT200000224A/en
Priority to PE2000001405A priority patent/PE20011095A1/en
Priority to ARP000106960A priority patent/AR027122A1/en
Priority to UY26514A priority patent/UY26514A1/en
Priority to EC2000003859A priority patent/ECSP003859A/en
Priority to US10/131,985 priority patent/US20030199440A1/en
Priority to US10/901,417 priority patent/US20050026836A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.
GBGB9930768.8A 1999-12-29 1999-12-29 Composition Ceased GB9930768D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB9930768.8A GB9930768D0 (en) 1999-12-29 1999-12-29 Composition
PCT/IB2000/001935 WO2001049309A2 (en) 1999-12-29 2000-12-21 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue
CA002395487A CA2395487A1 (en) 1999-12-29 2000-12-21 Composition for the treatment of damaged tissue
JP2001549676A JP2003519193A (en) 1999-12-29 2000-12-21 Composition for the treatment of damaged tissue
CO00097188A CO5271671A1 (en) 1999-12-29 2000-12-21 COMPOSITION FOR THE TREATMENT OF DONATED FABRICS
EP00981550A EP1242120A2 (en) 1999-12-29 2000-12-21 Combinations of growth factors and i:upa or i:mmp for the treatment of damaged tissue
AU18782/01A AU1878201A (en) 1999-12-29 2000-12-21 Composition for the treatment of damaged tissue
GT200000224A GT200000224A (en) 1999-12-29 2000-12-22 COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS.
ARP000106960A AR027122A1 (en) 1999-12-29 2000-12-27 COMPOSITION FOR THE TREATMENT OF DONATED FABRICS
PE2000001405A PE20011095A1 (en) 1999-12-29 2000-12-27 COMPOSITION THAT INCLUDES A GROWTH FACTOR AND A PROTEASE INHIBITOR USEFUL FOR THE TREATMENT OF DAMAGED TISSUES
UY26514A UY26514A1 (en) 1999-12-29 2000-12-28 "COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES".
EC2000003859A ECSP003859A (en) 1999-12-29 2000-12-28 COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS
US10/131,985 US20030199440A1 (en) 1999-12-29 2002-04-25 Composition for the treatment of damaged tissue
US10/901,417 US20050026836A1 (en) 1999-12-29 2004-07-28 Composition for the treatment of damaged tissue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930768.8A GB9930768D0 (en) 1999-12-29 1999-12-29 Composition

Publications (1)

Publication Number Publication Date
GB9930768D0 true GB9930768D0 (en) 2000-02-16

Family

ID=10867127

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9930768.8A Ceased GB9930768D0 (en) 1999-12-29 1999-12-29 Composition

Country Status (12)

Country Link
EP (1) EP1242120A2 (en)
JP (1) JP2003519193A (en)
AR (1) AR027122A1 (en)
AU (1) AU1878201A (en)
CA (1) CA2395487A1 (en)
CO (1) CO5271671A1 (en)
EC (1) ECSP003859A (en)
GB (1) GB9930768D0 (en)
GT (1) GT200000224A (en)
PE (1) PE20011095A1 (en)
UY (1) UY26514A1 (en)
WO (1) WO2001049309A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DE60141236D1 (en) 2000-10-16 2010-03-18 Genentech Inc Method of treatment using WISP polypeptides
DK1414487T3 (en) 2001-07-27 2006-10-09 Orthologic Corp Use of thrombin peptide derivatives for the treatment of chronic skin ulcers
WO2003029819A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Method of screening preventive/remedy for bone/joint diseases
EP1539214A4 (en) 2002-07-02 2008-01-02 Orthologic Corp Thrombin peptide derivatives
PT1559431E (en) 2003-12-31 2007-07-02 Orthologic Corp Pharmaceutical composition for thrombin peptide derivatives
AU2006301582B2 (en) 2005-10-07 2011-10-13 Msd Italia S.R.L. Matrix metalloproteinase 11 vaccine
KR20150072458A (en) * 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. Improved methods and compositions for wound healing
KR101629504B1 (en) * 2014-04-14 2016-06-10 주식회사 엘지생활건강 Composition for improving skin conditions containing a combination of cytokines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279840A (en) * 1988-04-28 1989-11-10 Wakunaga Pharmaceut Co Ltd Novel composition for external use
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
AR027122A1 (en) 2003-03-12
CO5271671A1 (en) 2003-04-30
WO2001049309A3 (en) 2002-02-28
JP2003519193A (en) 2003-06-17
UY26514A1 (en) 2001-07-31
EP1242120A2 (en) 2002-09-25
PE20011095A1 (en) 2001-10-27
WO2001049309A2 (en) 2001-07-12
CA2395487A1 (en) 2001-07-12
GT200000224A (en) 2002-06-15
AU1878201A (en) 2001-07-16
ECSP003859A (en) 2002-09-27

Similar Documents

Publication Publication Date Title
ES2145913T3 (en) METALOPROTEASE INHIBITORS.
MY133996A (en) Compounds for the treatment of ischemia
AP9901478A0 (en) Compounds for the treatment of ischemia.
MY131388A (en) Inhibitors of hiv protease useful for the treatment of aids.
MXPA05003253A (en) Novel pyrimidineamide derivatives and the use thereof.
DE69430385T2 (en) HIV Protease Inhibitors
GB9930768D0 (en) Composition
ATE245444T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PEG-ASPARAGINASE, FOR THE TREATMENT OF HIV INFECTIONS
MY126962A (en) A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
AU2001252278A1 (en) Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance
ATE329613T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING GROWTH HORMONES INHIBITORS OR THEIR BIOLOGICALLY ACTIVE FRAGMENTS FOR THE TREATMENT OF UTERINE MYOMAS
HUP0402645A2 (en) Pharmaceutical composition comprising a glitazone and 4-oxobutanoic acid, and the use thereof for treating diabetes
UA32314A (en) Method for treating necrotic pancreatitis
UA32315A (en) Technique for skin suturing

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)